Comparison of the Vitek 2 yeast susceptibility system with CLSI microdilution for antifungal susceptibility testing of fluconazole and voriconazole against Candida spp., using new clinical breakpoints and epidemiological cutoff values

2013 ◽  
Vol 77 (1) ◽  
pp. 37-40 ◽  
Author(s):  
Michael A. Pfaller ◽  
Daniel J. Diekema ◽  
Gary W. Procop ◽  
Michael G. Rinaldi
Keyword(s):  
Susceptibility Testing ◽  
Antifungal Susceptibility ◽  
Antifungal Susceptibility Testing ◽  
Candida Spp ◽  
Cutoff Values ◽  
Clinical Breakpoints ◽  
Vitek 2

scholarly journals Antifungal susceptibility testing.

1993 ◽  
Vol 6 (4) ◽  
pp. 367-381 ◽  
Author(s):  
J H Rex ◽  
M A Pfaller ◽  
M G Rinaldi ◽  
A Polak ◽  
J N Galgiani
Keyword(s):  
Susceptibility Testing ◽  
Incubation Temperature ◽  
Clinical Laboratory ◽  
Antifungal Susceptibility ◽  
Inoculum Size ◽  
Antifungal Susceptibility Testing ◽  
National Committee ◽  
Candida Spp ◽  
Interlaboratory Variability ◽  
Future Work

Unlike antibacterial susceptibility testing, reliable antifungal susceptibility testing is still largely in its infancy. Many methods have been described, but they produce widely discrepant results unless such factors as pH, inoculum size, medium formulation, incubation time, and incubation temperature are carefully controlled. Even when laboratories agree upon a common method, interlaboratory agreement may be poor. As a result of numerous collaborative projects carried out both independently and under the aegis of the Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards, the effects of varying these factors have been extensively studied and a standard method which minimizes interlaboratory variability during the testing of Candida spp. and Cryptococcus neoformans has been proposed. This review summarizes this work, reviews the strengths and weaknesses of the proposed susceptibility testing standard, and identifies directions for future work.

scholarly journals Frequency of candida infection among intensive care unit patients and their susceptibility profile

2021 ◽  
Vol 7 (3) ◽  
pp. 133-136
Author(s):  
Umar Farooq ◽  
Ayushi Jain ◽  
Sudhir Singh ◽  
Vasundhara Sharma ◽  
Shweta R Sharma ◽  
...  
Keyword(s):  
Intensive Care Unit ◽  
Susceptibility Testing ◽  
Antifungal Susceptibility ◽  
Central Line ◽  
Antifungal Susceptibility Testing ◽  
Clinical Samples ◽  
Human Beings ◽  
High Susceptibility ◽  
Vitek 2 ◽  
Isolated Species

species are responsible for causing many health care associated and central line associated infections. They are responsible for causing opportunistic infection in human beings. Genus of is composed of a heterogeneous group of organsims.Invasive infections of mainly caused by , , & . The main objective of this study was to isolates and Non- albicans and their antifungal susceptibility testing.Thestudy was carried out in the Department of Microbiology, in Tmu Hospital Moradabad. Total numbers of 806 clinical samples were processed in which 206 isolates were taken for . Isolation and antifungal susceptibility testing done by Vitek-2 system.Out of 206 samples 77(37%) were and 129(63%) were Non-albicans (NAC). Maximum isolated species were 77(37%), followed by 70(34%), 24(12%), C. glabrata 19(9%), 12(6%), C. krusei 3(1%), C.african 1(1%).Infection caused by NAC species have increased. was the most common isolated species. ,and were shown high susceptibility to fluconazole and voriconazole. Amphotericin B, Caspofungin, Micafungin and Flucytosine shows high susceptibility towards other candida species.

scholarly journals Corrigendum: Growth kinetics in Candida spp.: Differences between species and potential impact on antifungal susceptibility testing as described by the EUCAST.

2019 ◽  
Vol 57 (5) ◽  
pp. e8-e10 ◽  
Author(s):  
María Ángeles Bordallo-Cardona ◽  
Carlos Sánchez-Carrillo ◽  
Patricia Muñoz ◽  
Emilio Bouza ◽  
Pilar Escribano ◽  
...  
Keyword(s):  
Growth Kinetics ◽  
Susceptibility Testing ◽  
Antifungal Susceptibility ◽  
Antifungal Susceptibility Testing ◽  
Candida Spp ◽  
Potential Impact

scholarly journals Evaluation of the “Dip Effect” Phenomenon in Antifungal Susceptibility Testing of Candida spp. against Echinocandins by Use of Gradient Concentration Strips

2015 ◽  
Vol 53 (11) ◽  
pp. 3654-3659 ◽  
Author(s):  
Maria Siopi ◽  
Marilena Tsala ◽  
Nikolaos Siafakas ◽  
Loukia Zerva ◽  
Joseph Meletiadis
Keyword(s):  
Candida Albicans ◽  
Candida Tropicalis ◽  
Candida Glabrata ◽  
Susceptibility Testing ◽  
Antifungal Susceptibility ◽  
Antifungal Susceptibility Testing ◽  
Practical Approach ◽  
Candida Spp ◽  
Content Type ◽  
Inhibition Zones

The “dip effect” phenomenon complicates antifungal susceptibility testing with gradient concentration strips. Of 60Candidaisolates tested with the three echinocandins, this phenomenon was observed only for caspofungin with most (>90%)Candida albicans,Candida glabrata, andCandida tropicalisisolates and for isolates with CLSI MICs of ≤0.25 mg/liter. In order to facilitate MIC determination, a practical approach was developed using the inhibition zones at 32, 8, 2, and 1 mg/liter, increasing the agreement with the CLSI method >86%.

scholarly journals Antifungal Susceptibility Testing: Practical Aspects and Current Challenges

2001 ◽  
Vol 14 (4) ◽  
pp. 643-658 ◽  
Author(s):  
John H. Rex ◽  
Michael A. Pfaller ◽  
Thomas J. Walsh ◽  
Vishnu Chaturvedi ◽  
Ana Espinel-Ingroff ◽  
...  
Keyword(s):  
Amphotericin B ◽  
Susceptibility Testing ◽  
Antifungal Susceptibility ◽  
Antifungal Susceptibility Testing ◽  
Testing Methods ◽  
Clinical Value ◽  
Candida Spp ◽  
Testing Procedures ◽  
Reference Methods ◽  
Interlaboratory Reproducibility

SUMMARY Development of standardized antifungal susceptibility testing methods has been the focus of intensive research for the last 15 years. Reference methods for yeasts (NCCLS M27-A) and molds (M38-P) are now available. The development of these methods provides researchers not only with standardized methods for testing but also with an understanding of the variables that affect interlaboratory reproducibility. With this knowledge, we have now moved into the phase of (i) demonstrating the clinical value (or lack thereof) of standardized methods, (ii) developing modifications to these reference methods that address specific problems, and (iii) developing reliable commercial test kits. Clinically relevant testing is now available for selected fungi and drugs: Candida spp. against fluconazole, itraconazole, flucytosine, and (perhaps) amphotericin B; Cryptococcus neoformans against (perhaps) fluconazole and amphotericin B; and Aspergillus spp. against (perhaps) itraconazole. Expanding the range of useful testing procedures is the current focus of research in this area.

Sign in / Sign up

Export Citation Format

Share Document